Publications:

Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors.

Innovation (New York, N.Y.)

Du, Xiaojing X; Yang, Biwei B; An, Quanlin Q; Assaraf, Yehuda G YG; Cao, Xin X; Xia, Jinglin J

Publication Date: 2021-05-28

Variant appearance in text: EGFR: A289X

PubMed Link: 34557754

Variant Present in the following documents:

• Main text
• main.pdf

View BVdb publication page

Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors.

Innovation (Cambridge (Mass.))

Du, Xiaojing X; Yang, Biwei B; An, Quanlin Q; Assaraf, Yehuda G YG; Cao, Xin X; Xia, Jinglin J

Publication Date: 2021-05-28

Variant appearance in text: EGFR: A289X

PubMed Link: 34557754

Variant Present in the following documents:

• Main text
• main.pdf

View BVdb publication page

EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand.

Neuro-Oncology Advances

Hoogstrate, Youri Y; Vallentgoed, Wies W; Kros, Johan M JM; de Heer, Iris I; de Wit, Maurice M; Eoli, Marica M; Sepulveda, Juan Manuel JM; Walenkamp, Annemiek M E AME; Frenel, Jean-Sebastien JS; Franceschi, Enrico E; Clement, Paul M PM; Weller, Micheal M; van Royen, Martin E ME; Ansell, Peter P; Looman, Jim J; Bain, Earle E; Morfouace, Marie M; Gorlia, Thierry T; Golfinopoulos, Vassilis V; van den Bent, Martin M; French, Pim J PJ

Publication Date: 2020

Variant appearance in text: EGFR: A289x

PubMed Link: 32642719

Variant Present in the following documents:

• Main text
• vdz051.pdf

View BVdb publication page

Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas.

Cancers

Gao, Ya Y; Vallentgoed, Wies R WR; French, Pim J PJ

Publication Date: 2018-12-04

Variant appearance in text: EGFR: A289X

PubMed Link: 30518123

Variant Present in the following documents:

• Main text
• cancers-10-00489.pdf

View BVdb publication page